TABLE 1.

Summarized biomarkers of beneficial response to IL‐12 therapy including their respective locations and methods of detection

Potential correlate	Location/method of detection	Reference identified in
Increased IFN‐γ	Plasma, serum and peritoneal fluid by ELISA RNA, mRNA expression by RT‐PCR, intracellular flow cytometry Genomic DNA by cytokine genotyping assay	Gollob (16), Gollob (17), Parihar (19), Bekaii‐Saab (21), Alatrash (22), McMichael (23), Lenzi (25), Algazi (26),Heinzerling (30), Thaker (31)
Increased ratio of CD4+ and CD8+ T Cells to FoxP3+ T‐regulatory cells and M2 macrophages	Intratumoral infiltrate by flow cytometry, IHC staining	Gollob (17), Rook (24), Greaney (27), Algazi (26), Algazi (28), Heinzerling (30), Chiocca (32)
Increased IP‐10	Plasma, serum by ELISA mRNA expression by RT‐PCR	Parihar (19), Bekaii‐Saab (21), Alatrash (22), McMichael (23), Heinzerling (30)
Increased TNF‐α	Plasma, serum, peritoneal fluid by ELISA	Parihar (19), McMichael (23), Lenzi (25), Thaker (31)
Increased MIP‐1α	Plasma, serum by ELISA	Parihar (19), Bekaii‐Saab (21), Algazi (26), Algazi (28)
Increased MIG	Plasma, serum by ELISA mRNA expression by RT‐PCR	Parihar (19), Bekaii‐Saab (21), Alatrash (28)
Decreased VEGF, bFGF levels	Plasma, serum and peritoneal fluid by ELISA PEC expression by IHC staining	Younes (20), Lenzi (25), Thaker (31)